{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T03:46:14Z","timestamp":1782359174154,"version":"3.54.5"},"reference-count":60,"publisher":"Academy of Medicine, Singapore","issue":"2","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Acad Med Singap"],"abstract":"<jats:p>Introduction: Hydroxychloroquine (HCQ), originally an antimalarial drug, is currently used to treat multiple disorders, especially rheumatic diseases. Given its good efficacy and safety, HCQ is widely administered in pregnant patients. However, the safety profile of HCQ during pregnancy remains controversial due to limited research. In addition, HCQ has been reported to reduce preeclampsia in patients with systemic lupus erythematosus (SLE) and could potentially alleviate the symptom of preeclampsia. However, the clinical profile and molecular mechanism of HCQ in preeclampsia is yet to be fully understood.\n\nMethod: We reviewed the literature on HCQ treatment in pregnancy with rheumatic diseases and preeclampsia in PubMed and Web of Science. We also discussed the safety of long-term therapy with HCQ during pregnancy.\n\nResults: HCQ mainly modulates autoimmune response through inhibition of lysosomal function, toll-like receptor (TLR) signalling, nicotinamide adenine dinucleotide phosphate-mediated oxidative stress and autophagy. Benefits of HCQ in treating rheumatic diseases, including antiphospholipid syndrome, rheumatoid arthritis and Sjogren\u2019s syndrome during pregnancy, has been demonstrated in clinics. In particular, multiple clinical guidelines recommend HCQ as an indispensable therapeutic drug for pregnant patients with SLE. Additionally, it may potentially function in preeclampsia to improve clinical symptoms.\n\nConclusion: HCQ is effectively used for rheumatic diseases during pregnancy. The benefits of HCQ treatment in rheumatic diseases outweigh the risk of adverse reactions it induces in pregnant women.<\/jats:p>","DOI":"10.47102\/annals-acadmedsg.2023262","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T21:00:58Z","timestamp":1740776458000},"page":"113","source":"Crossref","is-referenced-by-count":2,"title":["Mechanisms and roles of hydroxychloroquine in pregnancy in rheumatic diseases"],"prefix":"10.47102","volume":"54","author":[{"given":"Lingjun","family":"Kong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"He","sequence":"additional","affiliation":[{"name":"Gamma Knife Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26165","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Ferreira PMP, de Sousa RWR, Ferreira JRO, et al. Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms. Pharmacol Res 2021;168:105582. DOI: 10.1016\/j.phrs.2021.105582","DOI":"10.1016\/j.phrs.2021.105582"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Chambers CD, Johnson DL, Xu R, et al. Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: A Prospective Cohort Study. Arthritis Rheumatol 2022;74:711-24. DOI: 10.1002\/art.42015","DOI":"10.1002\/art.42015"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155-66. DOI: 10.1038\/s41584-020-0372-x","DOI":"10.1038\/s41584-020-0372-x"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"M\u00fcller-Calleja N, Manukyan D, Canisius A, et al. Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. Ann Rheum Dis 2017;76:891-7. DOI: 10.1136\/annrheumdis-2016-210012","DOI":"10.1136\/annrheumdis-2016-210012"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Izquierdo JH, Bonilla-Abad\u00eda F, Ca\u00f1as CA, et al. Calcium, Channels, Intracellular Signaling and Autoimmunity. Reumatol Cl\u00edn 2014;10:43-7. DOI: 10.1016\/j.reumae.2013.11.004","DOI":"10.1016\/j.reumae.2013.11.004"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun Rev 2015;14:358-62. DOI: 10.1016\/j.autrev.2014.12.006","DOI":"10.1016\/j.autrev.2014.12.006"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Kroese SJ, de Hair MJH, Limper M, et al. Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births [published correction appears in J Immunol Res 2022;9783521]. J Immunol Res 2017;2017:2810202. DOI: 10.1155\/2017\/2810202","DOI":"10.1155\/2017\/2810202"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Chen YM, Lin CH, Lan TH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology (Oxford) 2015;54:1244-9. DOI: 10.1093\/rheumatology\/keu451","DOI":"10.1093\/rheumatology\/keu451"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Liu Y, Wei Y, Zhang Y, et al. Hydroxychloroquine significantly decreases the risk of preeclampsia in pregnant women with autoimmune disorders: a systematic review and meta-analysis. Clin Rheumatol 2023;42:1223-35. DOI: 10.1007\/s10067-022-06496-2","DOI":"10.1007\/s10067-022-06496-2"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Alle G, Guettrot-Imbert G, Larosa M, et al. Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in systemic lupus erythematosus patients. Rheumatology (Oxford) 2024;keae302. DOI: 10.1136\/annrheumdis-2024-eular.3981","DOI":"10.1136\/annrheumdis-2024-eular.3981"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001;10:401-4. DOI: 10.1191\/096120301678646137","DOI":"10.1191\/096120301678646137"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Braga A, Barros T, Faria R, et al. Systemic lupus erythematosus and pregnancy: A retrospective single-center study of 215 pregnancies from Portugal. Lupus 2021;30:2165-75. DOI: 10.1177\/09612033211050340","DOI":"10.1177\/09612033211050340"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Leroux M, Desveaux C, Parcevaux M, et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 2015;24:1384-91. DOI: 10.1177\/0961203315591027","DOI":"10.1177\/0961203315591027"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Balevic SJ, Cohen-Wolkowiez M, Eudy AM, et al. Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes. J Rheumatol 2019;46:57-63. DOI: 10.3899\/jrheum.180158","DOI":"10.3899\/jrheum.180158"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Canti V, Scarrone M, De Lorenzo R, et al. Low incidence of intrauterine growth restriction in pregnant patients with systemic lupus erythematosus taking hydroxychloroquine. Immunol Med 2021;44:204-10. DOI: 10.1080\/25785826.2020.1868652","DOI":"10.1080\/25785826.2020.1868652"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Abd Rahman R, Min Tun K, Kamisan Atan I, et al. New Benefits of Hydroxychloroquine in Pregnant Women with Systemic Lupus Erythematosus: A Retrospective Study in a Tertiary Centre. Rev Bras Ginecol Obstet 2020;42:705-11. DOI: 10.1055\/s-0040-1715140","DOI":"10.1055\/s-0040-1715140"},{"key":"ref16","unstructured":"National Clinical Research Center for Dermatologic and Immunologic Diseases; National Clinical Research Center for Obstetrics and Gynecology; Chinese Research Committee of Pregnancy and Reproduction in Autoimmune Rheumatic Diseases; Chinese Rheumatism Data Center, et al. Zhonghua Nei Ke Za Zhi 2022;61:1184-205."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Pons-Estel BA, Bonfa E, Soriano ER, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis 2018;77:1549-57. DOI: 10.1177\/0961203313512883","DOI":"10.1177\/0961203313512883"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2016;55:1693-7. DOI: 10.1093\/rheumatology\/kev404","DOI":"10.1093\/rheumatology\/kev404"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 2018;57:e1-e45. DOI: 10.1093\/rheumatology\/kex286","DOI":"10.1093\/rheumatology\/kex286"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2020;72:529-56. DOI: 10.1002\/art.41191","DOI":"10.1002\/art.41191"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736-45. DOI: 10.1136\/annrheumdis-2019-215089","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Schreiber K, Hunt BJ. Pregnancy and Antiphospholipid Syndrome. Semin Thromb Hemost 2016;42:780-8. DOI: 10.1055\/s-0036-1592336","DOI":"10.1055\/s-0036-1592336"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sciascia S, Hunt BJ, Talavera-Garcia E, et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol 2016;214:273.e1-273.e8. DOI: 10.1016\/j.ajog.2015.09.078","DOI":"10.1016\/j.ajog.2015.09.078"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Mekinian A, Lazzaroni MG, Kuzenko A, et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. Autoimmun Rev 2015;14:498-502. DOI: 10.1016\/j.autrev.2015.01.012","DOI":"10.1016\/j.autrev.2015.01.012"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Gerde M, Ibarra E, Mac Kenzie R, et al. The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. Thromb Res 2021;206:104-10. DOI: 10.1016\/j.thromres.2021.08.004","DOI":"10.1016\/j.thromres.2021.08.004"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Ruffatti A, Tonello M, Hoxha A, et al. Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. Thromb Haemost 2018;118:639-46. DOI: 10.1055\/s-0038-1632388","DOI":"10.1055\/s-0038-1632388"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome. Ann Rheum Dis 2017;76:476-85. DOI: 10.1136\/annrheumdis-2015-eular.3921","DOI":"10.1136\/annrheumdis-2016-209770"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296-304. DOI: 10.1136\/annrheumdis-2019-215213","DOI":"10.1136\/annrheumdis-2019-215213"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Barros T, Braga J, Abreu MI, et al. Sj\u00f6gren\u2019s syndrome and pregnancy: a Portuguese case-control study. Reumatologia 2022;60:311-7. DOI: 10.5114\/reum.2022.120754","DOI":"10.5114\/reum.2022.120754"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Ye S, Zhao X, Liu Y, et al. The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities. Clin Rheumatol 2023;42:1137-50. DOI: 10.1007\/s10067-022-06462-y","DOI":"10.1007\/s10067-022-06462-y"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Ballester C, Grobost V, Roblot P, et al. Pregnancy and primary Sj\u00f6gren\u2019s syndrome: management and outcomes in a multicentre retrospective study of 54 pregnancies. Scand J Rheumatol 2017;46:56-63. DOI: 10.3109\/03009742.2016.1158312","DOI":"10.3109\/03009742.2016.1158312"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Fierro JJ, Prins JR, Verstappen GM, et al. Preconception clinical factors related to adverse pregnancy outcomes in patients with systemic lupus erythematosus or primary Sj\u00f6gren\u2019s syndrome: a retrospective cohort study. RMD Open 2023;9:e003439. DOI: 10.1136\/rmdopen-2023-003439","DOI":"10.1136\/rmdopen-2023-003439"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Priori R, Gattamelata A, Modesti M, et al. Outcome of pregnancy in Italian patients with primary Sj\u00f6gren syndrome. J Rheumatol 2013;40:1143-7. DOI: 10.3899\/jrheum.121518","DOI":"10.3899\/jrheum.121518"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Bombardieri S, et al. EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis 2020;79:3-18. DOI: 10.1136\/annrheumdis-2019-216114","DOI":"10.1136\/annrheumdis-2019-216114"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Carsons SE, Vivino FB, Parke A, et al. Treatment Guidelines for Rheumatologic Manifestations of Sj\u00f6gren\u2019s Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain. Arthritis Care Res (Hoboken). 2017;69:517-27. DOI: 10.1002\/acr.22968","DOI":"10.1002\/acr.22968"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sj\u00f6gren\u2019s Syndrome [published correction appears in Rheumatology (Oxford). 2017;56:1828]. Rheumatology (Oxford) 2017;56:e24-e48. DOI: 10.1093\/rheumatology\/kex375","DOI":"10.1093\/rheumatology\/kex375"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Russell MD, Dey M, Flint J, et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2023;62:e48-e88. DOI: 10.1093\/rheumatology\/keac686","DOI":"10.1093\/rheumatology\/keac686"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2021;73:924-39. DOI: 10.1002\/acr.24596","DOI":"10.1002\/acr.24596"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82:3-18. DOI: 10.1136\/ard-2022-223356corr1","DOI":"10.1136\/ard-2022-223356corr1"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Lau CS, Chia F, Dans L, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 2019;22:357-75. DOI: 10.1111\/1756-185X.13513","DOI":"10.1111\/1756-185X.13513"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"de Moreuil C, Alavi Z, Pasquier E. Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. Br J Clin Pharmacol 2020;86:39-49. DOI: 10.1111\/bcp.14131","DOI":"10.1111\/bcp.14131"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Rector A, Mari\u0107 I, Chaichian Y, et al. Hydroxychloroquine in Lupus Pregnancy and Risk of Preeclampsia. Arthritis Rheumatol. Published online. 25 January 2024. DOI: 10.1002\/art.42793","DOI":"10.1002\/art.42793"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Hu Z, Gao R, Huang W, et al. Effect of Hydroxychloroquine on Lupus Activity, Preeclampsia and Intrauterine Growth Restriction in Pregnant Women with Systemic Lupus Erythematosus and\/or Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis. J Clin Med 2023;12:485. DOI: 10.3390\/jcm12020485","DOI":"10.3390\/jcm12020485"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Louchet M, Sibiude J, Peytavin G, et al. Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. Am J Obstet Gynecol MFM 2020;2:100159. DOI: 10.1016\/j.ajogmf.2020.100159","DOI":"10.1016\/j.ajogmf.2020.100159"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Gaffar R, Pineau CA, Bernatsky S, et al. Risk of Ocular Anomalies in Children Exposed In Utero to Antimalarials: A Systematic Literature Review. Arthritis Care Res (Hoboken) 2019;71:1606-10. DOI: 10.1002\/acr.23808","DOI":"10.1002\/acr.23808"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Kim DA, Rho S. Peters Anomaly in One Premature Twin Following Hydroxychloroquine Exposure During Pregnancy: A Case Report. Korean J Ophthalmol 2023;37:273-4. DOI: 10.3341\/kjo.2023.0007","DOI":"10.3341\/kjo.2023.0007"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Huybrechts KF, Bateman BT, Zhu Y, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol 2021;224:290.e1-290.e22. DOI: 10.1016\/j.ajog.2020.09.007","DOI":"10.1016\/j.ajog.2020.09.007"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Friedman DM, Kim M, Costedoat-Chalumeau N, et al. Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. Circ Arrhythm Electrophysiol 2020;13:e008686. DOI: 10.1161\/circep.120.008686","DOI":"10.1161\/CIRCEP.120.008686"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Klinger G, Morad Y, Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001;358:813-4. DOI: 10.1016\/s0140-6736(01)06004-4","DOI":"10.1016\/S0140-6736(01)06004-4"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003;48:3207-11. DOI: 10.1002\/art.11304","DOI":"10.1002\/art.11304"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Reynolds JA, Gayed M, Khamashta MA, et al. Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology (Oxford) 2023;62:1124-35. DOI: 10.1093\/rheumatology\/keac372","DOI":"10.1093\/rheumatology\/keac372"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Andersson NW, Skov L, Andersen JT. Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology (Oxford) 2021;60:2317-26. DOI: 10.1093\/rheumatology\/keaa592","DOI":"10.1093\/rheumatology\/keaa592"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"B\u00e9rard A, Sheehy O, Zhao JP, et al. Chloroquine and Hydroxychloroquine Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes Using Real-World Evidence. Front Pharmacol 2021;12:722511. DOI: 10.3389\/fphar.2021.722511","DOI":"10.3389\/fphar.2021.722511"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Diav-Citrin O, Blyakhman S, Shechtman S, et al. Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reprod Toxicol 2013;39:58-62. DOI: 10.1016\/j.reprotox.2013.04.005","DOI":"10.1016\/j.reprotox.2013.04.005"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez R, Gonc\u00e9 A, Gil MDM, et al. Efficacy and safety of hydroxychloroquine for treatment of mild SARS-CoV-2 infection and prevention of COVID-19 severity in pregnant and postpartum women: A randomized, double-blind, placebo-controlled trial. Acta Obstet Gynecol Scand 2024;103:602-10. DOI: 10.1111\/aogs.14745","DOI":"10.1111\/aogs.14745"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Clowse MEB, Eudy AM, Balevic S, et al. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med 2022;9:e000651. DOI: 10.1136\/lupus-2021-000651","DOI":"10.1136\/lupus-2021-000651"},{"key":"ref57","unstructured":"Limper M, de Leeuw K, Lely AT, et al. Diagnosing and treating antiphospholipid syndrome: a consensus paper. Neth J Med 2019;77:98-108."},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Belizna C, Pregnolato F, Abad S, et al. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmun Rev 2018;17:1153-68. DOI: 10.1016\/j.autrev.2018.05.012","DOI":"10.1016\/j.autrev.2018.05.012"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Schreiber K, Breen K, Cohen H, et al. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. Semin Thromb Hemost 2017;43:562-71. DOI: 10.1055\/s-0037-1603359","DOI":"10.1055\/s-0037-1603359"}],"container-title":["Annals of the Academy of Medicine, Singapore"],"original-title":[],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T02:54:24Z","timestamp":1782356064000},"score":1,"resource":{"primary":{"URL":"https:\/\/annals.edu.sg\/mechanisms-and-roles-of-hydroxychloroquine-in-pregnancy-in-rheumatic-diseases\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,27]]}},"URL":"https:\/\/doi.org\/10.47102\/annals-acadmedsg.2023262","relation":{},"ISSN":["2972-4066"],"issn-type":[{"value":"2972-4066","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}